Announcements Trials
Browse Landscape

Phase

Phase 1 21Phase 1/2 19Phase 2 15Phase 3 6Phase NA 4Phase EARLY_PHASE1 2Phase 4 2Phase 2/3 1

Status

Unknown 3Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Myeloid 3Lymphoid 1Head & Neck 1

Conditions

Breast Neoplasms 552Colorectal Neoplasms 246Neoplasms 232Prostatic Neoplasms 221Carcinoma, Non-Small-Cell Lung 196Stomach Neoplasms 153Leukemia, Myeloid, Acute 149Carcinoma, Hepatocellular 147Lung Neoplasms 137Rectal Neoplasms 135Multiple Myeloma 133Nasopharyngeal Carcinoma 112Colonic Neoplasms 106Neoplasm Metastasis 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Lymphoma 85Uterine Cervical Neoplasms 83Pancreatic Neoplasms 82Lymphoma, Large B-Cell, Diffuse 79Ovarian Neoplasms 78Leukemia 78Head and Neck Neoplasms 77Esophageal Neoplasms 74Lymphoma, Follicular 72Brain Neoplasms 70Squamous Cell Carcinoma of Head and Neck 65Recurrence 64Leukemia, Lymphocytic, Chronic, B-Cell 59Lymphoma, Non-Hodgkin 58Pain 56

Interventions

pegaspargase 2Methylprednisolone 2Etoposide 2spartalizumab 1Tegafur 1Mitomycin 1Lenalidomide 1Epirubicin 1Doxorubicin 1Dexamethasone 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × OTHER × Epstein-Barr Virus Infections × Clear all
NCT02363400 2025-08-19

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

National Health Research Institutes, Taiwan

Phase 3 Terminated
10 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT04832607 2025-07-18

TRACE

University Hospital Freiburg

Phase 3 Recruiting
149 enrolled

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT05775705 2023-03-20

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

Beijing Friendship Hospital

Phase 3 Not yet recruiting
25 enrolled
LymphoidMyeloid

Lymphoma, Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

NCT04084626 2022-01-05

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

Beijing Friendship Hospital

Phase 3 Unknown
40 enrolled

Epstein-Barr Virus Infections

NCT02912702 2016-09-23

L-DEP as an Initial Treatment for EBV-HLH

Beijing Friendship Hospital

Phase 3 Unknown
120 enrolled
Myeloid

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

NCT02631109 2016-08-04

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Beijing Friendship Hospital

Phase 3 Unknown
120 enrolled
Myeloid

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡